Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05085197 · ClinicalTrials.gov registry record · Phase 1
The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects
A Phase 1 study of Healthy, sponsored by Staidson Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05085197: Completed Phase 1 study of Healthy, sponsored by Staidson Biopharma.
NCT05085197 is a Phase 1 study of Healthy that has completed, run by Staidson Biopharma. The registered enrollment target is 32 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05085197, a Phase 1 study of Healthy, has completed, sponsored by Staidson Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants. Four kinds different doses and dose-matched placebo were administered under fasted conditions.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG STSA-1005 injection
Study Locations (1)
Kansas
- AltaSciences Clinical Kansas, Inc - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05085197
The ClinicalTrials.gov registry entry for NCT05085197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Staidson Biopharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05085197 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05085197 about?
NCT05085197 is a clinical study titled "The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects". This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants. Four kinds different doses and dose-matched placebo were administered under fasted conditions.
What is the current status of trial NCT05085197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-10-27. Estimated completion is 2022-04-05.
What conditions does trial NCT05085197 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05085197?
The interventions under investigation include: Placebo (DRUG), STSA-1005 injection (DRUG).
Who is sponsoring clinical trial NCT05085197?
This trial is sponsored by Staidson Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05085197 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.